| 2024-03-06 | Revance Therapeutics, Inc. RVNC | CEO | 30,000 0.0377% | $6.98 | $209,400 | -41.32% | ||
| 2024-02-23 | Sale | Glaukos Corporation GKOS | director | 4,560 0.0097% | $92.87 | $423,487 | +11.61% | |
| 2023-08-03 | Sale | Revance Therapeutics, Inc. RVNC | CEO | 26,279 0.0307% | $22.57 | $593,151 | -72.39% | |
| 2023-07-03 | Sale | Revance Therapeutics, Inc. RVNC | CEO | 26,279 0.0322% | $24.94 | $655,333 | -72.16% | |
| 2023-06-09 | Sale | Revance Therapeutics, Inc. RVNC | CEO | 31,279 0.0397% | $30.72 | $960,928 | -75.29% | |
| 2023-05-15 | Sale | Revance Therapeutics, Inc. RVNC | CEO | 70,447 0.0886% | $34.55 | $2.43M | -75.34% | |
| 2023-03-09 | Sale | Revance Therapeutics, Inc. RVNC | CEO | 70,390 0.0885% | $31.59 | $2.22M | -45.58% | |
| 2021-11-29 | Revance Therapeutics, Inc. RVNC | CEO | 40,000 0.0613% | $12.90 | $515,924 | +33.51% | ||
| 2017-11-07 | Revance Therapeutics, Inc. RVNC | director | 20,000 0.0637% | $26.96 | $539,168 | +9.42% |